Statehouses Filed 314 Bills Against Pharmacy Middlemen This Session. The Sharpest Ones All Guard the Same Doorway: Between the Patient and the Prescription

Across 314 state bills, the legislative battle over pharmacy benefit managers reveals a deep divide: is this a fight for government transparency and drug affordability, or a structural defense of the independent pharmacy market?

Yesterday, Iowa's state auditor released a report accusing pharmacy benefit managers — the middlemen who decide what a pharmacy gets paid and what a patient owes at the counter — of misusing Medicaid dollars, finding that payments to PBMs "vastly exceeded" what they paid pharmacies. The report landed in the middle of a live legal war: CVS sued Tennessee within days of Governor Lee signing the FAIR Rx Act on May 22, which bans PBMs from owning the pharmacies they reimburse, and Arkansas's ownership-divorce law is tied up in four lawsuits. Every state now regulates PBMs somehow. The question is what, exactly, each statehouse believes it is fighting.

So we pulled the whole pile: every bill filed since last October, in any of the fifty state legislatures, that uses the exact phrase "pharmacy benefit manager" — drawn from Open States, which aggregates all fifty statehouses — taking each bill's title plus its official abstract as one [[document]], dropping 17 appropriations bills that mention the phrase only in passing and 3 stubs too short to read, and keeping 314. Then we laid them out as a [[map]]: a picture where bills that say similar things sit near each other, and the directions the picture stretches along tell you what the legislatures actually disagree about.

The widest stretch — the first [[bearing]], the line everything in the pile splits along — runs between PBM and drug access regulation at one end and government transparency and records at the other. The first pole is the heart of the fight: bills that reach past the middleman's books to guard the path between a patient and a prescription. The farthest-out document on the whole map's main line is a New Jersey Senate bill whose entire public abstract reads: "Prohibits pre-approval or precertification of medical tests, procedures and prescription drugs covered under health benefits or prescription drug benefits plans." Its neighbors are more of the same — a companion bill for cancer treatments, another forbidding plans from cutting off "maintenance medications for chronic conditions" just because the patient's PBM changed. The opposite pole holds something we didn't order: a wing of Illinois public-records bills — one begins "Amends the Freedom of Information Act. Provides that records containing law enforcement in-car camera and officer-worn body camera video and audio recordings that a public body received from another public body are exempt from inspection or copying under the Act" — which mention pharmacy benefit managers only somewhere deep in the bill text, never in the title or abstract. We left them visible rather than trimming them quietly: anyone tracking "PBM legislation" by keyword is counting these too, and the map shows exactly how far from the real fight they sit.

Inside the real PBM mass, the next two splits are the three angers this fight is usually described by — and the map keeps them apart. One bearing separates price from practice: at one end, broad drug-pricing and affordability bills ("Establishes prescription drug pricing disclosure requirements and measures to reduce prescription drug costs," runs a New Jersey abstract); at the other, conduct regulation aimed at insurers and PBMs as businesses, including an Ohio bill that would flatly "prohibit various types of health care entities from being under common ownership" — the breakup anger, in statute form. Another bearing isolates pharmacist survival from benefit mechanics: at its far end Rhode Island's legislature passed a measure whose full text is its title — "HOUSE RESOLUTION RECOGNIZING THE VITAL ROLE OF INDEPENDENT COMMUNITY PHARMACIES IN RHODE ISLAND" — while the opposite end is occupied by Kentucky bills working the fine print, forbidding plans from charging a copay "for a prescription drug that is greater than the cash price." Deep-red Kentucky and deep-blue New Jersey sit at the same poles; nothing in these splits sorts the states by party.

What the map says, in the end, is that "PBM reform" is not one bill wave. It is a fight over patient access, a fight over price, a fight over the survival of the corner pharmacy, and a fight over who may own whom — sharing a single keyword. The Iowa auditor's report will be claimed by all four, and which one your statehouse is actually waging was written into the bill text months ago.